View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of M...

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis –PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis in MASH patients with compensated cirrhosis (F4) is planned to initiate in the second quarter of 2024– SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharm...

CPI Card Group Inc.: Update to credit analysis

Our credit view of this issuer reflects its leading position as a US provider of financial payment cards and services, constrained by its limited visibility into bank inventory levels.

 PRESS RELEASE

Warner Norcross + Judd LLP selects Intapp to strengthen client relatio...

Warner Norcross + Judd LLP selects Intapp to strengthen client relationship management PALO ALTO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: INTA), a leading global provider of AI-powered solutions for professionals at advisory, capital markets, and legal firms, today announced that corporate law firm Warner Norcross + Judd LLP has selected  as its relationship management platform. Leading strategic change“As a part of our firmwide growth strategy, we encourage our attorneys to deepen their relationships with current clients while effectively nurturing their networks to source ...

 PRESS RELEASE

Flywire survey: Luxury travelers planning to spend more on vacations a...

Flywire survey: Luxury travelers planning to spend more on vacations and take longer trips compared to last year Interest in luxury cruises increased nearly 70% Year-over-Year, signaling boon for ocean experiences Payment simplicity and security remain top requirements for discerning travelers BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FLYW), a global payments enablement and software company, has released its on luxury travelers' preferences, finding 90% of their vacations will be longer than ones they took a few years ago. 87% of the same group also plan to spend more on tr...

 PRESS RELEASE

EQS-News: ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR K...

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION 26.03.2024 / 13:30 CET/CEST The issuer is solely responsible for the content of this announcement. CSE: DTC     Börse Frankfurt: DTC    OTCQB: DTCFF      PRESSEMITTEILUNG ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARMTM-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002TM-KREBSIMPFSTOFFS DER ZWEITEN GENERATION Vanc...

 PRESS RELEASE

EQS-News: DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER AR...

EQS-News: Defence Therapeutics Inc. / Key word(s): Product Launch DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE 26.03.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement.   _________________________________________________________________ CSE: DTC  FSE: DTC  OTCQB: DTCFF       PRESS RELEASE   DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE   Vancouve...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Myriad Genetics Announces Foundational Patent Granted for Molecular Re...

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA...

 PRESS RELEASE

Flywire Partners with VTEX to Deliver Integrated Payment Experience to...

Flywire Partners with VTEX to Deliver Integrated Payment Experience to Higher Education Institutions across Latin America Flywire’s integration with VTEX provides a streamlined payment experience across entire student financial lifecycle Partnership underscores Flywire’s commitment to expansion throughout Latin America BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- (Flywire) (Nasdaq: FLYW), a global payments enablement and software company, has announced a strategic partnership with VTEX, the global enterprise digital commerce platform. Incorporating Flywire’s digital education payment sol...

Wedbush Research
  • Wedbush Research
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch